Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukemia by Parker, H. et al.
1 
 
Genomic disruption of the histone methyltransferase SETD2 in 1 
chronic lymphocytic leukemia 2 
Helen Parker 1*, Matthew JJ Rose-Zerilli 1*, Marta Larrayoz 1*,  Ruth Clifford 2, Jennifer 3 
Edelmann 3, Stuart Blakemore 1, Jane Gibson 4, Jun Wang 5, Viktor Ljungström 6, Tomasz K 4 
Wojdacz 1, Tracy Chaplin 5, Ali Roghanian 1, Zadie Davis 7, Anton Parker 7, Eugen Tausch 3, 5 
Stavroula Ntoufa 8, Sara Ramos 2, Pauline Robbe 2, Reem Alsolami 2, Andrew J Steele 1, 6 
Graham Packham 1, Ana E. Rodríguez-Vicente 9, Lee Brown 1, Feargal McNicholl 10, Francesco 7 
Forconi 1, Andrew Pettitt 11, Peter Hillmen 12, Martin Dyer 13, Mark S Cragg 1, Claude Chelala 5, 8 
Christopher C Oakes 14 Richard Rosenquist 6, Kostas Stamatopoulos 8, Stephan Stilgenbauer 3, 9 
Samantha Knight 2, Anna Schuh 2,David G Oscier 1,7 and Jonathan C Strefford 1 10 
1 Cancer Research UK Centre and Experimental Cancer Medicine Centre, Academic Unit of 11 
Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK,  12 
2 Oxford National Institute for Health Research Biomedical Research Centre/Molecular 13 
Diagnostic Centre, University of Oxford, Oxford, UK,  14 
3 Department of Internal Medicine III, Ulm University, Ulm, Germany,  15 
4 Centre for Biological Sciences, Faculty of Natural and Environmental Sciences, University of 16 
Southampton, UK,  17 
5 Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary’s, University of London, 18 
London, UK,  19 
6 Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala 20 
University, Sweden, 21 
7 Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK, 22 
8 Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, 23 
Greece. 24 
9 Department of Haematology, University Hospital of Salamanca-Biomedical Research 25 
Institute of Salamanca; IBMCC, Comprehensive Cancer Center Research, University of 26 
Salamanca-CSIC, Salamanca, Spain  27 
2 
 
10 Altnagelvin Area Hospital, Western Health and Social Care Trust, Londonderry, UK,  28 
11 Department of Molecular and Clinical Cancer Medicine, Royal Liverpool and Broadgreen 29 
University Hospitals NHS Trust, Liverpool L7 8XP, UK,  30 
12 Department of Haematology, St James's University Hospital, Leeds, UK,  31 
13 College of Medicine, Biological Sciences and Psychology, University of Leicester, UK,  32 
14 Division of Hematology, Department of Internal Medicine, The Ohio State University, 33 
Columbus, USA 34 
 35 
* These authors contributed equally to this manuscript 36 
Correspondence to: Professor Jonathan C Strefford, Cancer Genomics Group, Cancer Sciences 37 
Division, Somers Cancer Research Building, Southampton General Hospital, Tremona Road, 38 
Southampton SO16 6YD. Tel: 44 23 8079 5246. E-mail: JCS@soton.ac.uk 39 
Conflict of interests: The authors state that that there are no conflicts of interests. 40 
 41 
Text word count: 3623 42 
Abstract word count: 166 43 
Number figures/tables: 4/2 44 
Number references: 43 45 
Number supplementary figures/tables: 5/6 46 
  47 
3 
 
Abstract 48 
Histone methyltransferases (HMTs) are important epigenetic regulators of gene transcription and 49 
are disrupted at the genomic level in a spectrum of human tumors including hematological 50 
malignancies. Using high-resolution SNP-arrays, we identified recurrent deletions of the SETD2 locus 51 
in 3% (8/261) of chronic lymphocytic leukemia (CLL) patients. Further validation in two independent 52 
cohorts showed that SETD2 deletions were associated with loss of TP53, genomic complexity and 53 
chromothripsis. With next generation sequencing we detected mutations of SETD2 in an additional 54 
3.8% of patients (23/602). In most cases, SETD2-deletions or mutations were often observed as a 55 
clonal event and always as a mono-allelic lesion, leading to reduced mRNA expression in SETD2-56 
disrupted cases. Patients with SETD2 abnormalities and wild-type TP53 and ATM from five clinical 57 
trials employing chemotherapy or chemo-immunotherapy, had reduced progression-free and overall 58 
survival compared to cases wild-type for all three genes. Consistent with its postulated role as a 59 
tumor suppressor, our data highlights SETD2 aberration as a recurrent, early loss-of-function event 60 
in CLL pathobiology linked to aggressive disease. 61 
  62 
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Introduction 63 
The transfer of methyl groups from S-adenosyl methionine to lysine or arginine residues on histone 64 
proteins, catalyzed by histone methyltransferases (HMTs), is an important regulator of gene 65 
transcription. Accordingly, HMTs are disrupted by various mechanisms including chromosomal 66 
translocations, genomic loss and/or point mutations in both solid and hematological malignancies.1 67 
Among the increasing number of HMT aberrations identified in human malignancies, recurrent loss 68 
and/or inactivating mutations of the tumor suppressor gene SETD2, were initially identified in clear 69 
cell renal cell carcinoma (ccRCC)2 and subsequently in other solid tumors e.g. high grade gliomas.3 70 
Moreover, SETD2 mutations have been reported in a subset of patients with acute lymphoblastic 71 
leukemia4 and acute myeloid leukemia, especially those with rearrangements in the another HMT 72 
gene, MLL.5 SETD2 is the only enzyme that catalyzes the trimethylation of lysine 36 on histone 3 73 
(H3K36me3), one of the major chromatin marks associated with active transcription. Recent studies 74 
have linked SETD2 to the maintenance of genomic integrity, through coordination of homologous 75 
recombination repair after double strand breaks. The loss of SETD2 impairs DNA repair and enhances 76 
genomic instability, supporting its tumor suppressor role. 6-9  77 
Chronic lymphocytic leukemia (CLL) is characterized by remarkable clinical heterogeneity such that 78 
some patients pursue an indolent course while others require early treatment. Considerable effort 79 
has focused on understanding the genetic diversity that underpins this clinical heterogeneity. High-80 
resolution genomic arrays and next-generation sequencing have identified recurring novel regions of 81 
genomic copy-number aberrations (CNAs) like del(13q), del(11q), trisomy 12 and del(17p) and 82 
recurrent  driver mutations in genes such as TP53, ATM, SF3B1 and NOTCH1, respectively (reviewed 83 
in 10). Mutations frequently involve genes encoding proteins with important roles in cell signalling, 84 
cell cycle control, DNA repair and RNA-splicing and processing; however the reported incidence of 85 
mutations in chromatin modifiers is lower than in many other haematological malignancies.  86 
In this study, we report the identification of recurrent deletions and mutations of the SETD2 gene in 87 
large, well-characterized CLL cohorts. SETD2 lesions appear to represent early events in CLL 88 
pathogenesis, often co-existing with, but preceding TP53 abnormalities. They are associated with 89 
genomic complexity and chromothripsis, and identify a subgroup of patients with poor outcome.  90 
5 
 
Methods 91 
Patients 92 
We studied samples taken from 1006 CLL patients either at entry into one of five clinical trials or 93 
from a cohort of untreated patients with progressive disease managed at the Royal Bournemouth 94 
Hospital. Four randomized trials (ADMIRE, ARCTIC, UK CLL4 11, GCSG CLL8 12) compared chemo or 95 
chemo-immunotherapy regimens in fit previously untreated patients while the fifth trial (SCSG 96 
CLL2O) enrolled ultra-high risk patients who were either refractory to a purine analogue or were 97 
previously untreated with a 17p deletion. Further details of the clinical trials are provided in Table S1. 98 
All patients were diagnosed using standard morphologic and immunophenotypic criteria. Informed 99 
consent was obtained from all patients in accordance with the Helsinki declaration, and this study 100 
was approved by national or regional research ethics committees.  101 
Patients were grouped into three cohorts (discovery [n=261], extension [n=635] and ultra high-risk 102 
[n=110]); details of the cohort composition and SETD2 analysis are summarised in Table 1, 103 
Supplementary methods and Supplementary figure 1. DNA was extracted from CLL B cell samples 104 
(all with >80% tumour purity) and from matched germ-line DNA for SETD2-mutated cases as 105 
outlined in Supplementary methods. The assessment of established biomarkers was performed as 106 
previously described.13 572 and 602 samples were screened for SETD2 loss and mutation, 107 
respectively, with 168 cases screened for both loss and mutation. 108 
Genome-wide microarray-based copy number analysis 109 
DNA from 261 discovery and 110 ultra-high risk cases was amplified, labelled and hybridized to the 110 
Affymetrix SNP6.0 platform, aligned onto the human genome sequence (GRCh37) and analysed in 111 
Partek Genomics Suite (Partek Inc, Missouri, USA) as reported previously.14-18 DNA from 201 pre-112 
treatment extension cases (ADMIRE and ARCTIC) was hybridized to the Illumina HumanOmni1-Quad 113 
and HumanOmniS-8 platforms according to manufacturer’s protocols. 19,20 Further experimental 114 
details are provides in the Supplementary methods.  115 
Targeted re-sequencing and whole exome sequencing 116 
93 CLL samples from the discovery cohort (and five matched germ-line controls) were processed and 117 
analysed for mutations in SETD2 (all exons) and a number of clinically relevant genes with a bespoke 118 
Haloplex Target Enrichment system (Agilent Technologies) (Supplementary Methods Table 1) and 119 
processed and analysed as previously reported.21 An additional 231 cases from our pre-treatment 120 
extension cohort were screened for SETD2 mutations using a TruSeq Custom Amplicon panel 121 
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(Illumina Inc. San Diego, CA, USA) as previously described.20,22 All the variants identified by both 122 
platforms were annotated against dbSNP (build 135) and functional prediction was also performed 123 
using SIFT and Polyphen2 analysis. Somatically-acquired SETD2 mutations (n=4) were also identified 124 
in the recent whole exome sequencing (WES) study of 278 matched tumor and germ-line cases from 125 
the GCSG CLL8 study 23. Additional experimental details are provided in the Supplementary methods. 126 
Sanger validation 127 
Variants in SETD2 were subjected to validation by conventional Sanger-based sequencing of PCR 128 
products obtained from tumor [n=11] and where possible, paired normal genomic DNA [n=5]. The 129 
expression of SETD2 mutations at mRNA level was also tested in samples with available material 130 
[n=4]. Primers for DNA or mRNA validation are listed in Table S2. 131 
Quantitative RT-PCR 132 
Total RNA was isolated from purified CLL cells of 36 patient samples using RNeasy columns (Qiagen) 133 
and reversed transcribed using the Improm™II RT-PCR kit (Promega, UK) according to the 134 
manufacturer’s instruction. Primers and probes for the housekeeping genes (18s) and target genes 135 
(CCDC12, NBEAL2, KIF9, KLHL18, SETD2) were selected using the Universal Probe Library (Roche 136 
Applied Science, UK) (Table S3). Two independent assays were designed to ascertain expression of 3’ 137 
and 5’ SETD2. Normal B-cell mRNA was use to normalize the expression of each gene by delta-delta 138 
CT method as previously described.24  139 
Statistical analysis 140 
Statistical analysis was performed with SPSS v22. Differences between samples were analysed by U-141 
Mann Whitney test. Progression-free survival (PFS) and overall survival (OS) were calculated for 142 
clinical trial samples from randomization. Survival analysis was performed by Kaplan-Meier and log-143 
rank analysis. Significant differences were considered with P-values lower than 0.05. 144 
  145 
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Results 146 
Recurrent deletions of 3p are a feature of CLL 147 
We identified 1024 acquired CNAs (mean 3.9, range 0–45) in our discovery cohort (Table S4). 148 
Deletions of chromosome 3p [del(3p)] were observed in 8 patients (3%), ranged from 0.45-81 Mb in 149 
size (Table S5), and identified a well delineated MDR between genomic location 46.96-47.39 Mb, 150 
containing the genes CCDC12, NBEAL2, SETD2, KIF9 and KLHL18 (Figure 1A). We compared the 151 
expression of these genes by qRT-PCR in 3p deleted [n=6] versus non-3p deleted patients [n=8] 152 
(Figure 1C). We were not able to detect the expression of KIF9 mRNA in CLL or normal B-cells.  153 
Within the MDR, the HMT gene SETD2 was significantly under-expressed, measuring by two 154 
different assays targeting the 3’ or 5’ region of the mRNA (p<0.0001 for both assays).  155 
We then aimed to confirm the presence of 3p deletions and refine the MDR in our extension cohorts. 156 
Firstly, we identified nine del(3p) cases (4.5%) in our extension pre-treatment cohort, permitting the 157 
MDR to be refined to the SETD2 and KIF9 loci (47.12-47.36 Mb, Figure 1A and Table S5). Across our 158 
discovery and pre-treatment extension cohorts, SETD2 deletions were present in 17/461 cases 159 
(3.7%), significantly associated with deletions and/or mutations of TP53 (p=0.003) and genomic 160 
complexity (≥3 deletions25, p=0.04)(Figure 1B). GISTIC 2.0 analysis 26, an algorithm for identifying 161 
statistically significant regions of CNA above an estimated background rate (FDR q-value <0.25), 162 
showed that in 39 TP53 deleted cases (del(3p), n=15), the SETD2 region on 3p21.31, was deleted at a 163 
significant frequency (q-value=0.001), ranked third after del(13q) and del(17p) (Figure S2).  164 
Interestingly, SETD2 deletions without concomitant TP53/ATM abnormalities [n=6] also exhibited 165 
significantly more genomic complexity than wildtype patients (p=0.01. Figure 1D). Two SETD2-166 
deleted cases showed evidence of chromosome 3 chromothripsis (based on >10 CNAs per 167 
chromosome18) (Figure 1A-B). In the ultra-high risk cohort, SETD2-deletions were detected in 9% of 168 
cases [10/110], and were significantly enriched compared to the pre-treatment cohort (p=0.009). All 169 
ten had loss of TP53 and five had concomitant chromosome 3 chromothripsis (Figure 1B). To further 170 
establish the significance of our SETD2 deletion in cases with chromosome 3 chromothripsis, we 171 
mapped all recurrently 3p deletions in these cases. This analysis showed that whilst additional 172 
regions of recurrent deletion were observed on 3p, the only regions shared across all patients 173 
included the SETD2 locus (Table S6). 174 
We analysed SETD2 expression in an extended cohort of patients with 3p deletions [n=16], and again 175 
the expression was diminished in these patients compared to wild-type patients (P=0.0068; Figure 176 
S3). In order to study the clonal nature of the SETD2 deletions, we assigned each genomic CNA with 177 
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a relative copy-number value by normalizing CNA intensity values from array features. We excluded 178 
regions with gain and sex chromosome CNAs from the analysis. The cut off for normal copy number 179 
was established between 1.7 and 2.3. We could infer that the 3p deletion was in the dominant clonal 180 
population in 11/18 (61%) cases with data available for analysis (Figure S4). 181 
SETD2 mutations in CLL 182 
To identify somatic gene mutations, we initially employed targeted re-sequencing of 93 discovery 183 
cohort cases and identified 122 non-silent mutations (non-synonymous n=80, frameshift indel n=20, 184 
splicing n=9, nonframeshift indel n=6, stopgain n=6, stoploss n=1) targeting 37 genes in 71/93 cases 185 
(mean 1.8, range 1-4). Sanger sequencing confirmed 93.6% of the tested variants [n=79], whilst the 186 
remaining unconfirmed variants were present at low read depth (n=3) or in a low percentage of 187 
mutant reads (n=2). We found ATM [n=14], TP53 [n=14], NOTCH1 [n=20] and SF3B1 [n=15] 188 
mutations at a frequency expected for the studied cohort, which aligns with published data and 189 
demonstrates the validity of the re-sequencing platform. We identified non-synonymous SETD2 190 
mutations in four (4.3%) discovery cases (p.D99G, p.Q1545K, p.W1306*, p.E1955Q) (Figure 2A-B). 191 
Sanger sequencing validated that all of the SETD2 mutations were present in tumor DNA. We 192 
obtained matched germ-line DNA from three patients and confirmed that the mutations were 193 
somatically acquired (p.D99G, p.W1306*, p.E1955Q) (Figure S5A).  194 
To corroborate this preliminary observation, we investigated 231 cases of our pre-treatment 195 
extension cohort by TruSeq amplicon-based sequencing. We identified an additional nine (3.9%) 196 
SETD2 mutations (p.A50T, p.L89F, p.P167L, p.N535S, p.E670K, p.M1742L, p.M1889T (x2), p.I2295M) 197 
(Figure 2A-B). Sanger sequencing confirmed each SETD2 variant in the tumour material and in two 198 
cases with germ-line material available, the variants were somatically acquired. Assessment of WES 199 
data of the CLL8 study23 samples included in our pre-treatment extension cohort, revealed the 200 
presence of somatically-acquired SETD2 mutations in 4/278 cases (1.4%), namely, 201 
p.EEEELQSQQ1919fs, p.L1804fs, p.VLEYC1576del, p.V1190M. None of these SETD2 mutations (Table 202 
2) are annotated in COSMIC27. During the preparation of this manuscript, a study performed by 203 
Puente et al. in 506 CLL patients also described both SETD2 mutations (0.8% of cases) and deletions 204 
in 3p (2% of cases) whose MDR encompassed SETD2 28 whilst Landau et al identified SETD2 205 
mutations in 8/538 (1.5%) cases 23. 206 
In total, across our cohorts there were 15 somatically-acquired SETD2 variants (15/602; 2.5%). An 207 
additional eight variants that could not be examined in germ-line material were either absent (n=3), 208 
reported to have a very low prevalence (n=5) in 1000 Genomes project or have a sub-clonal variant 209 
allele frequency (%VAF <0.45, (n=1); Table 2). Therefore, whilst these eight variants are predicted to 210 
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be functionally deleterious, we cannot exclude that the minority may be rare germ-line variants as 211 
they exhibit clonal variant allele frequencies in the tumor material.  212 
We were able to confirm the expression of the SETD2 mutations at mRNA level in four of our 213 
patients with available material (p.D99G, p.Q1545K, p.E1955Q, p.E670K) (Figure S5A), and qRT-PCR 214 
analysis of three SETD2 mutated samples showed that SETD2 mRNA expression was reduced 215 
compared to wild-type patients (P=0.035; Figure S3). 216 
We performed integrative analysis of 93 cases from our discovery cohort with Haloplex re-217 
sequencing and SNP6.0 copy number data available, by employing the ABSOLUTE algorithm.29 This 218 
approach estimates the cancer cell fraction (CCF) harboring a given mutation by correcting for 219 
sample purity and local copy number changes. Mutations were classified as clonal if the CCF 220 
was >0.95 with a probability >0.5, and sub-clonal otherwise.30 In additional cases with proven-221 
somatic SETD2 mutations (n=4) and paired copy number data from our pre-treatment validation 222 
cohorts, we performed this estimation by manually correcting for tumor sample purity and local 223 
copy-number. Our analysis demonstrated the expected sub-clonal distribution of established gene 224 
mutations, such as TP53, ATM, SF3B1 and NOTCH1. Interestingly, all our somatically acquired SETD2 225 
mutations exhibited a clonal CCF, suggesting that these mutations may be early events in the 226 
evolution of CLL (Figure 2C-D & Figure S5B-C), although further studies are required to confirm this 227 
observation. 228 
SETD2 aberrations are associated with inferior progression free- and overall survival 229 
Finally, we analysed the impact of SETD2 abnormalities (deletion or somatically-acquired mutation) 230 
on progression-free (PFS) and overall survival (OS) in front-line trial patients. We observed a 231 
significantly shorter PFS in cases with SETD2 abnormalities that were wild-type for TP53/ATM [n=7], 232 
compared to cases wild-type for TP53/ATM/SETD2 [n=62] (PFS: 30 vs. 48 months; p=0.003) (Figure 233 
2E). The same patients with SETD2 abnormalities [n=7] also had a shorter OS than wild-type patients 234 
[n=62] (OS: 34 vs. 92 months; p<0.001) (Figure 2F). Whilst these data suggest that SETD2 aberration 235 
may be clinically relevant, further investigation in larger cohorts is needed to understand their full 236 
impact on survival. 237 
  238 
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Discussion  239 
This study was based on an initial high-resolution SNP6.0 array analysis of 261 untreated patients 240 
with progressive CLL which identified a recurrent deletion of the short arm of chromosome 3 in 3% 241 
of cases (n=8). The MDR included the CCDC12, NBEAL2, SETD2, KIF9 and KLHL18 genes, of which 242 
SETD2 was the most significantly under-expressed in tumor cells. We then identified clonal, 243 
somatically-acquired SETD2 mutations in 4.3% of this cohort; no mutated case had a concomitant 244 
SETD2 deletion.  245 
The SETD2 gene encodes a 230 kDa protein that is non-redundantly responsible for all trimethylation 246 
of lysine 36 on histone H3 (H3K36me3),31,32 a mark that is associated with actively transcribed 247 
regions and is involved in transcriptional elongation and splicing. 33 In addition, recent studies have 248 
linked this epigenetic histone mark to other important cellular processes such as the regulation of 249 
mismatch repair, efficient homologous recombination and the maintenance of genomic stability.7-9 250 
In vitro inhibition of Setd2 decreases global levels of H3K36me3 and impairs the recruitment of the 251 
mismatch recognition protein hMutSα onto chromatin, thereby preventing appropriate DNA 252 
mismatch repair. Cells lacking the Setd2 protein display microsatellite instability and have elevated 253 
levels of spontaneous mutations.7,34-36 Inactivating SETD2 mutations were first described in ccRCC2,6, 254 
subsequently in other solid tumors such as paediatric high-grade gliomas and most recently in a 255 
subset of patients with acute lymphoid and myeloid leukemias. 2,5,37,38 SETD2 mutations in ccRCC are 256 
frequently associated with 3p deletions resulting in loss of both SETD2 and VHL genes, while in acute 257 
leukemias, SETD2 mutations may be bi-allelic but 3p loss is rare. SETD2 genomic abnormalities are 258 
associated with decreased H3K36me3 levels, a distinctive DNA methylation signature6 and 259 
chemoresistance in paediatric acute lymphoblastic leukemia 39. In MLL-rearranged cells from acute 260 
leukemic patients, Setd2 knockdown is implicated in disease initiation and progression by promoting 261 
the self-renewal capacity of leukemic stem cells. 262 
In view of the role of SETD2 disruption in tumorigenesis and the identification of SETD2 263 
abnormalities in our discovery cohort, we then accrued samples from other patient cohorts, 264 
including the GCLLSG CLL8 cohort in which 3p deletions had also been detected 18, to confirm the 265 
incidence of SETD2 disruption and evaluate its biological and clinical consequences in CLL. Previously 266 
untreated patients sampled at randomization to chemo or chemo-immunotherapy trials had a 267 
similar incidence of 3p deletions (4.5%) to that seen in the discovery cohort while a higher incidence 268 
of loss (9%) was found in the ultra-high risk cohort. The inclusion of additional cohorts enabled a 269 
smaller MDR to be defined, including SETD2 and KIF9, implicating SETD2 as the key deleted gene. 270 
The incidence of SETD2 mutations was comparable in all cohorts tested, no synonymous mutations 271 
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were identified and when germ-line material was tested, all mutations were somatically acquired. 272 
The diverse sequencing strategies utilized in this current study precluded the application of 273 
computational tools like MutSigCV 40, an algorithm that identifies significantly mutated genes by 274 
accounting for background mutation rate, DNA replication time and the gene size. However, we did 275 
assess the SETD2 background mutation rate, expression level and replication timing data from 276 
Lawrence et al 40 demonstrating that SETD2 shares no properties associated with false-positive 277 
candidate cancer genes (Figure S7). The recent studies by Puente et al and Landau et al, published 278 
during the preparation of this manuscript confirms the rare but recurrent nature of SETD2 279 
abnormalities 23,28. SETD2 deletions were not over-represented by analysis of WES generated copy 280 
number data in the work by Landau and the mutation frequencies of both studies were lower than 281 
those in our study. The different frequencies reported in these two studies could be explained by 282 
cohort composition, as our study included ultra-high risk CLL and patients randomized to clinical 283 
trials. 284 
As we found SETD2 mRNA expression to be down regulated in cases with either SETD2 deletion or 285 
mutations and as we did not observe bi-allelic SETD2 abnormalities, we assessed whether SETD2 286 
may also be deregulated by DNA methylation. Kulis and co-workers41 reported no differential 287 
methylation levels in the SETD2 gene body and promoter regions (15 and 9 CpG probes), respectively 288 
between unmutated or mutated CLL or major cytogenetic sub-types and SETD2 mRNA expression 289 
was not correlated with gene methylation status [doi:10.1038/ng.2443: Supplementary tables 5 & 290 
11]41. Preliminary analysis of our own unpublished Illumina 450K methylation array data also 291 
demonstrated no differences between mutated and unmutated CLL for these probes (Figure S6). In 292 
addition, when we analysed SETD2 expression in a published CLL dataset 293 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2466)44 using the Oncomine portal 294 
(https://www.oncomine.org),42 we observed a heterogeneous pattern. Reduced levels are evident in 295 
the minority of patients, which given our observed association between SETD2 deletion and 296 
expression could imply gene deletion in those Oncomine samples with low mRNA expression. 297 
Together, this suggests that DNA methylation does not play a substantial role in regulating SETD2 298 
expression in B-CLL cells, as previously noted in acute leukemia 5. 299 
Across all cohorts, SETD2 deletion was found in both IGHV mutated and unmutated cases but was 300 
strongly associated with TP53 loss and mutation, likely accounting for its higher incidence in the 301 
ultra -high risk cohort. We also noted an association with genomic complexity even in cases lacking a 302 
TP53 or ATM abnormality, consistent with the role of SETD2 in maintaining genomic stability. 303 
Moreover, we identify several SETD2 deletions that appeared to be the result of chromothripsis. The 304 
somatically-acquired SETD2 mutations showed a comparable genomic distribution to those 305 
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previously described in other tumors and were predicted to have deleterious functional 306 
consequences. Furthermore, their association with significantly reduced mRNA expression in those 307 
cases analysed, suggest that they either directly affect mRNA expression, or co-exist with other 308 
defects in transcriptional control at this locus. Interestingly, we did not observe a statistically 309 
significant association between SETD2 mutations and TP53 abnormalities or genomic complexity, the 310 
implication of which may be differing functional consequences of mono-allelic loss and mutation.  311 
In our study, both SETD2 deletions and mutations often appeared to be clonal and may precede 312 
TP53 abnormalities in at least some cases. Setd2 has been shown to directly regulate the 313 
transcription of a subset of genes via cooperation with the transcription factor p53,43 and the link 314 
between SETD2 and TP53 is an interesting association worthy of functional validation. It is possible 315 
that the SETD2 alterations present in our CLL cases may contribute to further inactivation of p53-316 
mediated checkpoint control, a situation that has been proposed in ccRCC.8 The low frequency of 317 
SETD2 disruption and the association with TP53 abnormalities hinder an accurate assessment of its 318 
clinical consequences. Nevertheless, we observed a shorter PFS and OS in patients with SETD2 but 319 
no TP53 or ATM abnormalities compared to cases wild type for all three genes. In support of this 320 
preliminary clinical observation, it has been shown that 3p deletions in head and neck squamous 321 
carcinoma (HNSCC) are associated with reduced survival. 44 Furthermore, the authors showed that 322 
the co-existence of a TP53 abnormality with del(3p) decreased survival further, an observation that 323 
we could not confirm in our cohort. 324 
In summary, our current study provides the first comprehensive analysis of CNAs and mutations 325 
targeting the SETD2 gene in a large cohort of patients with CLL. We find somatic deletions and 326 
mutations in ~7% of CLL patients requiring treatment. These associate with TP53 dysfunction, 327 
genomic complexity and chromothripsis and may be early clonal events. Functional studies are now 328 
warranted to elucidate the exact biological importance of SETD2 in CLL pathogenesis, but our data 329 
adds to a growing body of evidence suggesting a role for H3K36me3 in tumorigenesis that may be 330 
exploited for the development of novel therapeutic approaches. 331 
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Figure Legends 477 
Figure 1. SETD2 deletions in our discovery, extension and ultra-high risk cohorts 478 
Figure 1A. SNP6.0 data for the del(3p) cases. Genomic location is indicated by the ladder to the left. 479 
Each column represents one patient. Loss, gain and normal copy-number are shown as blue, red and 480 
white, respectively. The black box indicates the MDR, and is displayed in greater detail for our 481 
discovery and extension cohorts. The genes in the MDR with their transcriptional direction are 482 
displayed in the middle, with the MDR from the discovery and extension cohorts shown by the red 483 
and purple bars, respectively. 1B. Matrix displaying the biomarkers and genomic features associated 484 
with del(3p) cases with the discovery, extension and ultra-high risk cases shown in red, purple and 485 
yellow, respectively. 1C. Real-time PCR expression for the five genes localized in the discovery MDR 486 
in cases with or without del(3p). All the samples were negative for KIF9. 18s was employed as 487 
housekeeping gene. Expression in normal B-cells was used as a normalization sample. Mean ± SD is 488 
represented. 1D. Scatterplots displaying the number of CNA observed in subgroups of our cohort 489 
(excluding ultra-high risk cases). Cases were assigned to a subgroup using a hierarchical model; 490 
presence of del(17p) and/or TP53 mutation, then del(11q) and/or ATM mutation, then del(3p) cases 491 
with and without TP53 abnormalities and then wild-type (WT) cases containing no del(17p), del(11q), 492 
del(3p) or mutations in ATM and TP53. Mean ± SD is represented.  493 
Figure 2. SETD2 mutations in our discovery and extension cohorts 494 
Figure 2A. Schematic diagram of the Setd2 protein with their key functional domains. Mutations are 495 
displayed on the diagram. The colour denotes the cohort, and the filled circles are mutations that 496 
have been confirmed as somatically acquired. 2B. Matrix displaying the biomarkers and genomic 497 
features associated with SETD2 mutated cases in the discovery (red) and extension (purple) cases. 2C. 498 
Analysis of the clonality for SETD2 and other recurrently mutated genes on CLL. For each case the 499 
cancer cell fraction (CCF) is derived manually or with the ABSOLUTE algorithm. Only somatically 500 
acquired validated mutations are displayed (cases 69, 100, S21 and 88).  The number of mutations (n) 501 
for each gene in the analysis is shown (bottom). 2D. Percentage of cases harboring clonal or 502 
subclonal mutations for each of the genes displayed. 2E. Kaplan-Meier and log-rank analysis for 503 
progression-free survival (PFS) in patients carrying SETD2 abnormalities (“SETD2 ab”) but wild-type 504 
for TP53 or ATM deletion and/or mutation compared to those with TP53 abnormalities (“TP53 ab”) 505 
and those wild-type for TP53, ATM and SETD2 (“Wild-type”). 2F. Kaplan-Meier and log-rank analysis 506 
for overall survival (OS) in the same categories described in E. 507 
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Table 2. SETD2 mutated cases from our discovery and extension cohorts and 
published data           
 
Patient 
ID SETD2 Mutation cDNA change 
SETD2 Mutation protein 
change 
Functional prediction 
(Polyphen2;SIFT) 
Somatically acquired 
validated dbSNP 
MAF 1000 
Genomes 
Mutation 
Taster Conserved 
D
i
s
c
o
v
e
r
y
 
c
o
h
o
r
t
 
69 c.5863G>C p.E1955Q   yes rs761536283 - P M.Musculus 
100 c.296A>G p.D99G -;D yes - - M M.Musculus 
255 c.4633C>A p.Q1545K P;T ND - - M D.Melano 
S21 c.3918G>A p.W1306* D;D yes - - M G.Gallus 
E
x
t
e
n
s
i
o
n
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o
h
o
r
t
 
(
i
n
c
l
u
d
e
s
 
C
L
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c
a
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e
s
)
 
149 c.2008G>A p.E670K P;D yes rs374976472 - M G.Gallus 
88 c.5224A>C p.M1742L P;D yes M D.Rerio 
4273 c.148G>A p.A50T D;D ND rs191985301 0.020% (1/5008) P M.Musculus 
4530 c.6885A>G p.I2295M B;D ND rs150476239 0.020% (1/5008) M D.Melano 
4546 c.500C>T p.P167L B;- ND rs78682369 0.020% (1/5008) P not conserved  
4715 c.5666T>C p.M1889T P;D ND rs148097513 0.040% (2/5008) M G.Gallus 
4172 c.5666T>C p.M1889T P;D ND rs148097513 0.040% (2/5008) M G.Gallus 
4426 c.A1604G p.N535S B;T ND - - P M.Musculus 
4426 c.C265T p.L89F B,D ND - - P M.Musculus 
#266 
c.5755-
5781delGAAGAGGAAGAATTGCAGT
CACAAC 
p.EEEELQSQQ1919fs -;- yes - - M M.Musculus 
#278 c.5411_5412delAC p.L1804fs -;- yes - - M partly conserved 
#269 c.4727_4741delTCCTAGAATATTGTG p.VLEYC1576del -;- yes - - M M.Musculus 
#313 c.3568G>A p.V1190M B;T yes - - P M.Musculus 
a
l
#
 
a
n
d
 
P
u
e
#028 c.6433G>T p.G2145* -;D yes - - M M.Musculus 
#065 c.4973C>G p.S1658* -;T yes - - M M.Musculus 
*15 c.2225C>G p.S742* -;T yes - - M partly conserved 
*#141 c.6985C>T p.Q2329* -;T yes - - M not conserved  
*#141 c.7616A>T p.K2539I D;D yes - - M M.Musculus 
*177 c.3876-3877delGT p.Y1293fs -;- yes - - M M.Musculus 
Footnote:ND: Not done, due to lack of germline material. PolyPhen2 prediction (B = Benign; P = Probably Damaging; D = Damaging; - = No prediction). SIFT prediction (D = Damaging; T = Tolerated; - = No prediction). MAF 
(minimal allele frequency in 1000 Genomes project). MutationTaster2 prediction (P=polymorphism; M=disease causing). Underlined text indicates an AID/APOBEC recognition motif. Mutation annotation was performed 
against COSMIC v 73 and no overlapping mutations were found. *Cases included in Puente et al and # Landau et al  
 
